PRMT1 and metabolic dysfunction-associated steatotic liver disease: Forcing expression of PRMT1 in the liver increased VLDL secretion and fasting blood glucose levels in normal mice under physiological conditions, suggesting that PRMT1 was a potential therapeutic target of NAFLD.